3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 3
2
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Uterine Cervical Neoplasms
2
Interventions
Cisplatin
53
Paclitaxel
27
Carboplatin
22
Brachytherapy
18
Radiotherapy
17
human papillomavirus vaccine, L1 type 16, 18
12
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
12
Gemcitabine
12
Topotecan
8
Vaccines, Synthetic
7
Platinum
7
Papillomavirus Vaccines
7
Radiation
6
Bevacizumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
Neoadjuvant Therapy
5
Chemotherapy, Adjuvant
5
pembrolizumab
4
Vinorelbine
4
Radiotherapy, Intensity-Modulated
4
Pemetrexed
4
Drug Therapy
4
Taxes
3
Surgical Procedures, Operative
3
Ondansetron
3
Irinotecan
3
Dexamethasone
3
Chemoradiotherapy
3
tisotumab vedotin
2
specific substance maruyama
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Uterine Cervical Neoplasms
×
tisotumab vedotin
×
Clear all
NCT06459180
2026-05-27
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
686 enrolled
NCT04697628
2026-02-24
innovaTV 301
Seagen Inc.
Phase 3
Completed
502 enrolled
18 charts
1 FDA